PMS-ANAGRELIDE CAPSULE

Country: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

ANAGRELIDE (ANAGRELIDE HYDROCHLORIDE MONOHYDRATE)

থেকে পাওয়া:

PHARMASCIENCE INC

এটিসি কোড:

L01XX35

INN (International Name):

ANAGRELIDE

ডোজ:

0.5MG

ফার্মাসিউটিকাল ফর্ম:

CAPSULE

রচনা:

ANAGRELIDE (ANAGRELIDE HYDROCHLORIDE MONOHYDRATE) 0.5MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

100

প্রেসক্রিপশন টাইপ:

Prescription

Therapeutic area:

PLATELET-REDUCING AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0131875001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2006-01-06

পণ্য বৈশিষ্ট্য

_pms-ANAGRELIDE (anagrelide hydrochloride) _
_Page 1 of 37_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-ANAGRELIDE
Anagrelide Hydrochloride Capsules
Capsules, 0.5 mg anagrelide (as anagrelide hydrochloride monohydrate),
Oral
House Standard
Platelet-Reducing Agent
PHARMASCIENCE INC.
6111 Royalmount Avenue, Suite #100
Montréal, Québec
H4P 2T4
www.pharmascience.com
Submission Control Number: 274306
Submission Control No: 236846
Date of Initial Authorization:
January 6, 2006
Date of Revision:
October 3, 2023
_pms-ANAGRELIDE (anagrelide hydrochloride) _
_Page 2 of 37_
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
09/2023
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
09/2023
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage
Adjustment
09/2023
4 DOSAGE AND ADMINISTRATION, 4.5 Missed Dose
03/2022
7 WARNINGS AND PRECAUTIONS
03/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
.....................................................................................................................
4
1.1
Pediatrics
.....................................................................................................................
4
1.2
Geriatrics
.....................................................................................................................
4
2
CONTRAINDICATIONS
........................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................................... 5
4
DOSAGE AND ADMINISTRATION
....................................